Scinogy

Executive Summary

Scinogy is an Australian company specializing in automated, single-use cell therapy manufacturing platforms. Founded in 2020 and headquartered in Melbourne, the company has developed the Rotea system, a flexible, closed-process platform designed to enhance efficiency and preserve cell viability for both autologous and allogeneic therapies. By reducing production costs and streamlining the transition from clinical trials to commercial scale, Scinogy addresses a critical bottleneck in the cell therapy industry. With a lean team of 10-50 employees, the company operates at the platform stage, positioning itself as a key enabler for cell therapy developers seeking scalable and cost-effective manufacturing solutions. The global cell therapy market faces significant manufacturing challenges, including high costs and complex scalability. Scinogy's Rotea platform offers a compelling solution by leveraging automation and closed-system design to improve yields and reduce contamination risks. The company's technology is applicable across a wide range of cell therapies, from CAR-T to stem cell treatments. As the sector continues to grow, Scinogy is well-positioned to capture market share through strategic partnerships and potential regulatory clearances. The company's focus on innovation and operational efficiency makes it a promising player in the cell therapy manufacturing space, with the potential to accelerate the availability of life-saving therapies.

Upcoming Catalysts (preview)

• Q4 2026Strategic partnership with a top-10 pharmaceutical company for Rotea adoption in CAR-T manufacturing70% success
• Q2 2027FDA 510(k) clearance for a key consumable component of the Rotea system60% success
• Q1 2027Series B funding round to expand commercial operations and R&D80% success